Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 30, 2021
Subject: Announcement of changes to respiratory product sales reporting and presentation of revised 2020 Pharmaceutical turnover data.
GSK is updating its sales reporting structure effective Q1 2021 to better reflect product life-cycle stages and strategic focus. This filing provides restated 2020 data to align with the new format.
Key Financial Metrics (2020 Full Year)
The filing provides detailed turnover data for the year ended December 31, 2020, under the revised reporting format. Total Pharmaceutical turnover was £17,056 million, representing a reported decline of 3% (1% decline at constant exchange rates).
| Category | Total Turnover (£m) | Reported Growth (%) | CER Growth (%) |
|---|---|---|---|
| New and Specialty Pharmaceuticals | 8,335 | 11 | 12 |
| Respiratory | 2,360 | 31 | 32 |
| HIV | 4,876 | - | 1 |
| Immuno-Inflammation & Other Specialty | 727 | 19 | 20 |
| Oncology | 372 | 62 | 62 |
| Established Pharmaceuticals | 8,721 | (13) | (12) |
| Established Respiratory | 4,640 | (10) | (9) |
| Dermatology | 425 | (4) | (1) |
Note: The filing does not provide consolidated profit, cash flow, debt, or liquidity metrics for the full group; it focuses exclusively on Pharmaceutical product sales turnover.
Material Changes and Reporting Adjustments
The primary material change is a reclassification of product lines to ensure consistency in reporting:
- Established Respiratory: Sales of Relvar/Breo Ellipta, Incruse Ellipta, and Arnuity Ellipta are moved from the "Respiratory" category to "Established Respiratory" within "Established Pharmaceuticals."
- Respiratory Category: Will now primarily report Trelegy Ellipta, Nucala, and Anoro Ellipta.
- HIV Category: Sales of Epzicom/Kivexa and Selzentry are incorporated into the "Other HIV" line.
These changes result in a shift of revenue from the "New and Specialty" segment to the "Established" segment for the affected respiratory products in comparative periods.
Key Product Performance Highlights (2020)
- Trelegy Ellipta: Reported 58% growth (59% CER).
- Nucala: Reported 29% growth (30% CER).
- Dovato: Reported growth of >100% (CER >100%).
- Juluca: Reported 35% growth (36% CER).
- Triumeq: Reported decline of 10% (9% CER decline).
- Relvar/Breo Ellipta: Reported 16% growth (17% CER) under the new "Established Respiratory" classification.
Guidance, Outlook, and Risks
Outlook: The filing does not contain forward-looking financial guidance or management commentary regarding future earnings or market conditions. It is strictly a disclosure of reporting methodology changes and historical data restatement.
Risks/Contingencies: No specific risks or contingencies are detailed in this document. The filing notes that the information is not statutory accounts and that 2020 data is derived from the full Group accounts published in the Annual Report 2020.
Investor Verification Checklist
- Segment Reclassification: Verify how the reclassification of Relvar/Breo Ellipta and Incruse Ellipta impacts year-over-year growth comparisons for the "New and Specialty" vs. "Established" segments.
- Full Year 2020 Accounts: Cross-reference the turnover figures provided here with the full Annual Report 2020 to confirm total group revenue and profit metrics not included in this 6-K.
- Constant Exchange Rate (CER): Review the CER growth percentages to understand underlying performance excluding currency fluctuations, as GSK emphasizes this metric.
- Product Lifecycle: Assess the strategic implication of moving key respiratory products to "Established" status, which may signal a shift in R&D focus or patent cliff management.